北京大学医学部机构知识库
Advanced  
IR@PKUHSC  > 北京大学第二临床医学院  > 血液科  > 期刊论文
学科主题: 临床医学
题名:
Haploidentical hematopoietic SCT may be superior to conventional consolidation/maintenance chemotherapy as post-remission therapy for high-risk adult ALL
作者: Sun, Y-Q1,2; Wang, J.1,2; Jiang, Q.1,2; Xu, L-P1,2; Liu, D-H1,2; Zhang, X-H1,2; Liu, K-Y1,2; Huang, X-J1,2,3
刊名: BONE MARROW TRANSPLANTATION
发表日期: 2015
DOI: 10.1038/bmt.2014.195
卷: 50, 期:1, 页:20-25
收录类别: SCI
文章类型: Article
WOS标题词: Science & Technology
类目[WOS]: Biophysics ; Oncology ; Hematology ; Immunology ; Transplantation
研究领域[WOS]: Biophysics ; Oncology ; Hematology ; Immunology ; Transplantation
关键词[WOS]: ACUTE LYMPHOBLASTIC-LEUKEMIA ; STEM-CELL TRANSPLANTATION ; HLA-MISMATCHED/HAPLOIDENTICAL BLOOD ; BONE-MARROW-TRANSPLANTATION ; SINGLE-CENTER ; REMISSION ; OUTCOMES ; RELAPSE ; MULTICENTER ; EXPERIENCE
英文摘要:

Only 30% of high-risk adult ALL patients in their first complete remission (CR1) are able to receive an HLA-matched sibling stem cell transplant. The role of haploidentical hematopoietic SCT (haplo-HSCT) in post-remission therapy is not well established. Recently, we developed a novel protocol for unmanipulated haploidentical transplantation. In this study, we compared haplo-HSCT with conventional consolidation and maintenance chemotherapy in adult high-risk ALL patients. Between January 2000 and December 2012, 104 patients received conventional chemotherapy and 79 patients received haplo-HSCT. Patients who underwent haplo-HSCT had significantly improved 3-year OS (72.5% vs 26.6%; P < 0.001), 3-year disease-free survival (DFS) (63.9% vs 21.1%; P < 0.001) and 3-year relapse (18.7% vs 60.5%; P < 0.001) rates. The non-relapse mortality (NRM) rate was not different between patients treated with haplo-HSCT vs chemotherapy (19.2% vs 14.4%; P = 0.80). In multivariate analysis, the only factor associated with improved OS, better DFS and low risk of relapse was haplo-HSCT. The only factor associated with high NRM was enrollment before 2006. In conclusion, haplo-HSCT may be an option for adults with high-risk ALL in CR1 who do not have an HLA-matched donor.

语种: 英语
WOS记录号: WOS:000347806800005
Citation statistics:
内容类型: 期刊论文
URI标识: http://ir.bjmu.edu.cn/handle/400002259/59716
Appears in Collections:北京大学第二临床医学院_血液科_期刊论文

Files in This Item:

There are no files associated with this item.


作者单位: 1.Peking Tsinghua Ctr Life Sci, Beijing, Peoples R China
2.Peking Univ, Peoples Hosp, Inst Hematol, Beijing 100044, Peoples R China
3.Beijing Key Lab Hematopoiet Stem Cell Transplanta, Beijing, Peoples R China

Recommended Citation:
Sun, Y-Q,Wang, J.,Jiang, Q.,et al. Haploidentical hematopoietic SCT may be superior to conventional consolidation/maintenance chemotherapy as post-remission therapy for high-risk adult ALL[J]. BONE MARROW TRANSPLANTATION,2015,50(1):20-25.
Service
Recommend this item
Sava as my favorate item
Show this item's statistics
Export Endnote File
Google Scholar
Similar articles in Google Scholar
[Sun, Y-Q]'s Articles
[Wang, J.]'s Articles
[Jiang, Q.]'s Articles
CSDL cross search
Similar articles in CSDL Cross Search
[Sun, Y-Q]‘s Articles
[Wang, J.]‘s Articles
[Jiang, Q.]‘s Articles
Related Copyright Policies
Null
Social Bookmarking
Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit
所有评论 (0)
暂无评论
 
评注功能仅针对注册用户开放,请您登录
您对该条目有什么异议,请填写以下表单,管理员会尽快联系您。
内 容:
Email:  *
单位:
验证码:   刷新
您在IR的使用过程中有什么好的想法或者建议可以反馈给我们。
标 题:
 *
内 容:
Email:  *
验证码:   刷新

Items in IR are protected by copyright, with all rights reserved, unless otherwise indicated.

 

 

Valid XHTML 1.0!
Copyright © 2007-2017  北京大学医学部 - Feedback
Powered by CSpace